BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37657395)

  • 1. Topoisomerase IIα immunoexpression in feline mammary carcinomas: A correlation with Ki67 immunoexpression and the mitotic count.
    Łopuszyński W; Brzana A; Szczubiał M; Bulak K; Śmiech A
    Res Vet Sci; 2023 Nov; 164():104992. PubMed ID: 37657395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
    Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
    Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
    Mattila R; Alanen K; Syrjänen S
    Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
    Harris LN; Broadwater G; Abu-Khalaf M; Cowan D; Thor AD; Budman D; Cirrincione CT; Berry DA; Winer EP; Hudis CA; Hayes DF; Friedman P; Ellis M; Dressler L
    J Clin Oncol; 2009 Jul; 27(21):3430-6. PubMed ID: 19470942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
    Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
    Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
    Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
    Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
    Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
    Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
    Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
    PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.
    Zhao H; Yu H; Liu Y; Wang Y; Cai W
    Clin Neuropathol; 2008; 27(2):83-90. PubMed ID: 18402387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
    Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
    Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
    Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
    Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.